Active ingredientThalidomideCat. No. P-T081-001CAS 50-35-1Family · Pharmaceutical analytical standards
Thalidomide
An immunomodulator synthesised in the 1950s that acts on the protein cereblon; in the United States it has been approved since 1998 for erythema nodosum leprosum, a painful complication of leprosy, and since 2006 for multiple myeloma. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?In 1964 the physician Jacob Sheskin, in Jerusalem, tried it on a critically ill leprosy patient: after sleeping for hours the man could get out of bed unaided, and that chance discovery led to clinical trials in leprosy.
Go to the active ingredient →Active ingredientThalidomideCat. No. P-T081-001CAS 50-35-1
Isotopically labelledThalidomide-d4Cat. No. P-T081-002CAS 1219177-18-0
Impurity(R)-ThalidomideCat. No. P-T081-003CAS 2614-06-4
ImpurityThalidomide Impurity 1Cat. No. P-T081-004CAS 26581-81-7
ImpurityThalidomide Impurity 2Cat. No. P-T081-005CAS 1479889-22-9
Impurity4-Hydroxy ThalidomideCat. No. P-T081-006CAS 5054-59-1
Impurity5-Hydroxy ThalidomideCat. No. P-T081-007CAS 64567-60-8
Impuritycis-5'-Hydroxy ThalidomideCat. No. P-T081-008CAS 203450-07-1
ImpurityN-Hydroxy ThalidomideCat. No. P-T081-009CAS 126663-38-5
ImpurityS-ThalidomideCat. No. P-T081-011CAS 841-67-8No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.